Edition:
India

People: ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

30.19USD
12:07am IST
Change (% chg)

$-0.09 (-0.30%)
Prev Close
$30.28
Open
$30.56
Day's High
$31.49
Day's Low
$30.03
Volume
42,512
Avg. Vol
41,766
52-wk High
$86.67
52-wk Low
$29.38

Walsh, Patrick 

Mr. Patrick D. Walsh has been appointed as Interim President, Chief Executive Officer, Director of the Company effective 5/11/2020. He is President & Managing Member of Diligence Team, LLC, a consulting practice he founded and is based in Durham, North Carolina. From 2015 to February 2019, Mr. Walsh was the chief executive officer of Avista Pharma, a private equity backed global provider of contract manufacturing, development and analytical testing services to pharmaceutical and biotechnology clients. Prior to Avista, from 2010 to 2014, Mr. Walsh was the chief executive officer of AAIPharma Services Corporation in Wilmington, North Carolina, a private equity backed global provider of contract manufacturing services. Mr. Walsh’s earlier career includes serving as chief executive officer of Kadmus Pharmaceuticals, Inc., in Irvine, California, and serving as president and chief operating officer of publicly-traded Gensia Sicor Pharmaceuticals, Inc. Mr. Walsh currently serves as an independent director of the Board of Directors of Avid Bioservices, a publicly-traded company based in Tustin, California and serves on its nominating committee. He is also an independent director of the Board of Directors of MedPharm LTD, a privately held company in Durham, North Carolina, and serves on its compensation committee. He is also an Operating Partner to healthcare private-equity firm Ampersand Capital, based in Wellesley, Massachusetts. Mr. Walsh is a member of the Board’s Audit and Finance and Compensation Committees. Mr. Walsh is nominated for re-election based on his 30-plus years of experience leading successful pharmaceutical manufacturing and development organizations and his significant prior experience as an independent director.

Basic Compensation

Total Annual Compensation, USD 77,081
Restricted Stock Award, USD 132,182
Long-Term Incentive Plans, USD --
All Other, USD 94,071
Fiscal Year Total, USD 303,334

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Brown

403,654

Patrick Walsh

303,334

Stephen Carey

2,156,390

Robert Schrepfer

2,160,980

James Marken

1,398,770

Thomas Haughey

315,278
As Of  31 Dec 2019